Products
Litifilimab Biosimilar Monoclonal Antibody (BDCA-2) for Research
Cat No.: GMP-Bios-INN-1262
Anti-CLEC4C therapeutic antibody (Pre-made Litifilimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Litifilimab (development code BIIB059) is a humanized monoclonal antibody targeting CLEC4C (BDCA-2). It is developed by Biogen for systemic and cutaneous lupus erythematosus. It is in Phase III clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1262-1mg | 1mg | 3090 |
| GMP-Bios-INN-1262-10mg | 10mg | |
| GMP-Bios-INN-1262-100mg | 100mg | |
| GMP-Bios-INN-1262-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Litifilimab biosimilar, Whole mAb, Anti-CLEC4C Antibody: Anti-CLEC4C/CD303/C-type lectin domain family 4 member C/Blood dendritic cell antigen 2 (BDCA-2) therapeutic antibody |
| INN Name | Litifilimab |
| Target | CLEC4C |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | Biogen Idec |
| Conditions Approved | na |
| Conditions Active | Systemic lupus erythematosus;Cutaneous lupus erythematosus |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
